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feeding syndrome (TFS) and hyperglycemic hyperosmolar nonketotic
syndrome (HHNS). He developed life-threatening hypernatremia from an
osmotic urea diuresis that was appropriately treated by replacing both the
FWD as well as ongoing free water losses calculated from the EFWC.
A 37 year-old man in a persistent vegetative state from a left thalamic
hemorrhage status post ventriculostomy and PEG tube placement was
admitted with sepsis and HHNS. He was receiving large amounts of Jevity
1.2. He had acute kidney injury due to severe volume depletion from an
osmotic urea diuresis. BUN was 200 mg/dL, sodium was 165 mEq/L,
glucose was 635 mg/dL, and serum osmolality was 449 mOsm/kg. To
prevent the development of cerebral edema from overly rapid correction of
hyperosmolality, he was started on an insulin drip and hypernatremia was
allowed to persist until the hyperglycemia was fully normalized. This was
followed by correcting the hypernatremia over 3 days. He was urinating up
to about 4 L/day of mostly electrolyte free water. Using the FWD to arrive
at the rate of free water administration, he would only have received 2 L of
free water per day and hypernatremia would have persisted. Instead, he
required about 4.5 L/day of free water as calculated by the FWD and EFWC
together, and his hypernatremia resolved as expected.
Our patient presented with a triad of TFS including hypernatremia,
dehydration, and azotemia. Rapidly increased ﬂuid loss from sepsis and
HHNS initially caused severe hypernatremia. Only by using the
combination of FWD and EFWC calculations could we have arrived at the
appropriate rate of free water administration.
http://dx.doi.org/10.1016/j.krcp.2012.04.571
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IATROGENIC PERSISTENT HYPOPHOSPHATEMIA IN A SIMULTANEOUS
LIVER-KIDNEY TRANSPLANT RECIPIENT
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Hypophosphatemia from renal phosphate wasting during the immediate
postoperative kidney transplant period is common and improves with
supplementation. We report a case of hypophosphatemia secondary to
small bowel bypass surgery and over the counter antacid use in a patient
with stage 4 chronic kidney disease (CKD) many years after simultaneous
liver-kidney transplant (SLKT).
A 43-year-old man with a history of alcoholic end-stage liver disease and
hepatorenal syndrome status post SLKT 5 years prior presented with
recurrent small bowel obstruction which persisted despite conservative
treatment. Following exploratory laparotomy, he had a jejunal bypass
surgery due to the intra-operative ﬁnding of jejunum adherent to a single
mass. Due to the friability of the tissue, lysis of the adhesions was felt to be
unsafe. Postoperatively, he developed hypophosphatemia and severe
malnutrition due to short bowel syndrome. He required total parenteral
nutrition which led to improvement in serum phosphorus. However,
hypophosphatemia recurred and the lowest level of 1.1 mg/dl occurred
during the transition from parenteral nutrition to partial enteral nutrition.
On review of medication, he had been taking over the counter antacids for
‘‘indigestion’’. Serum calcium was low normal and intact parathyroid
hormone was within normal range. The patient also had vitamin D
deﬁciency with a total 25-OH vitamin D of 23 ng/ml. The serum
phosphorus improved after stopping antacids but remained persistently
low normal despite oral supplementation, and he continues to require
intermittent intravenous phosphate supplementation.
Although hyperphosphatemia is common in CKD, hypophosphatemia
can occur from overzealous dietary restrictions and use of phosphate
binders. Aluminum hydroxide is a potent phosphate binder commonly
found in over the counter antacids. Ongoing review of medications (both
prescription and over the counter) is important to prevent
hypophosphatemia. In addition, intestinal bypass, especially jejunal
bypass, contributes to hypophosphatemia, and our case underscores the
importance of the jejunum in phosphate absorption.
http://dx.doi.org/10.1016/j.krcp.2012.04.572
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LIFE-THREATENING HYPERNATREMIA IN A CASE OF DIABETES
INSIPIDUS/PANHYPOPITUITARISM
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Department of Medicine, University of Hawaii, Honolulu, Hawaii
Management of diabetes insipidus (DI) accompanied by
panhypopituitarism requires understanding of the relationships between
ADH and thyroid/glucocorticoid tone. Low thyroid/glucocorticoid tone
decreases free water clearance which protects against DI and may lead to
hyponatremia while high thyroid/glucocorticoid tone may unmask DI and
facilitate hypernatremia.
A 31 year-old man with DI/panhypopituitarism was stable until his
levothyroxine was incorrectly lowered based on TSH levels. He became
hypothyroid and was hospitalized 3 times over 1 month for recurring
altered mental status and mild hyponatremia. DDAVP was repeatedly held
with rapid onset of polyuria resulting severe hypernatremia. On the last
admission, he presented with altered mental status from sepsis. Serum
sodium was 135 mmol/l. He was made NPO and treated with stress dose
hydrocortisone and ﬂudrocortisone. DDAVP was held for the mild
hyponatremia. Serum sodium rapidly elevated to 168 mmol/l after only 12
hours. DDAVP was restarted with liberalization of diet to unlimited free
water access causing rapid downward sodium correction.
Hypernatremia almost always results from iatrogenic causes. In our case,
holding DDAVP for hyponatremia resulted in rapid onset of hypernatremia
and volume depletion. Stress dose glucocorticoids further unmasked DI.
Thirst and free access to water which typically protects patients with un-
replaced DI were not operational due to his NPO status which contributed
to the rapid rise in serum sodium.
Water balance is controlled by thyroid, glucocorticoid, and principally
ADH working at the renal effector level while the RAAS principally controls
sodium balance. Together these hormones tightly regulate serum sodium
concentration. Managing hospitalized patients with DI/panhypopituitarism
requires knowledge of the intricate interplay between ADH and thyroid/
glucocorticoid tone to minimize the risk for dangerous sodium ﬂuctuations.
It is usually better to err on the side of mild hyponatremia than holding
DDAVP in these complex patients which can lead to life threatening
hypernatremia.
http://dx.doi.org/10.1016/j.krcp.2012.04.573
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CALCIMIMETICS AND DELAYED PARATHYROIDECTOMY IN A KIDNEY
TRANSPLANT RECIPIENT
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Persistent hyperparathyroidism affects renal outcomes and mortality.
After kidney transplantation, cinacalcet is not approved as treatment for
hyperparathyroidism. Parathyroidectomy, on the other hand, reverses
electrolytes and mineral bone metabolism in almost all cases. Early
parathyroidectomy may increase the chance of resolving
hyperparathyroidism.
A 58–year-old man with ESRD status post deceased donor kidney
transplantation 3 years prior presented with bone aches. He had persistent
hypercalcemia and hypophosphatemia secondary to hyperparathyroidism.
Serum calcium ranged 9.3–11.4 mg/dl and serum phosphorus was
decreased with a lowest value of 2.1 mg/dl. Intact PTH level was elevated
to 487 pg/ml and total 25–OH vitamin D was 20 ng/ml. Bone density
studies indicated osteopenia. He refused parathyroidectomy and was
treated with cinacalcet. Because of persistent hyperparathyroidism, he
underwent subtotal parathyroidectomy. Postoperatively, he required high
phosphorus diet, phosphate supplements, and cinacalcet to maintain
normal serum phosphorus levels. Intact PTH was still elevated with the
level of 188 pg/ml while he continued cinacalcet.
Normally, parathyroidectomy is performed 1 year posttransplantion
unless severe bone disease, refractory hypercalcemia, or difﬁculty
controlling phosphate wasting occurs. Phosphate wasting from
hyperparathyroidism in our patient indicated parathyroidectomy;
however, the surgery was delayed for 3 years while cinacalcet had been
used. Post parathyroidectomy, hyperparathyroidism still persisted. Both
cinacalcet and parathyroidectomy are imperfect to reverse
hyperparathyroidism. Timely parathyroidectomy may determine the
reversal of electrolyte and metabolic bone diseases; however, a delayed
procedure may not have the same beneﬁt. Since hyperparathyroidism is
associated with higher incidence of kidney allograft dysfunction and
postoperative mortality, should there be a level where pretransplant
parathyroidectomy is performed?
http://dx.doi.org/10.1016/j.krcp.2012.04.574
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